axumin pet scan locations

Locations due to COVID-19 especially for vulnerable patients. Kindly note that not every procedure is available at all of our locations.

Characterizing And Mitigating Bladder Radioactivity On 18f Fluciclovine Pet Ct Journal Of Nuclear Medicine Technology

August 18 2021 Share SPOKANE WA - Cancer Care Northwest CCNW is.

. Online Appointment Request Complete the form below to schedule an appointment. Cancer Care Northwest Brings New Advanced Axumin PETCT Scan to Eastern Washington Posted. The Shields network makes it easily accessiblewe have sites that generally cover every region of.

For years we have been able to detect. Axumin is an FDA-approved Medicare-covered scan that can achieve early detection of recurrent prostate cancer after surgery or radiation. Bone Density CT Fluoroscopy exams 2D3D Mammography screening and diagnostic Nuclear Medicine and SPECT-CT Ultrasound X-ray Coronary Calcium CT Scan.

The scan time is about an hour during which the patient lies on his or her back. Select your chosen clinic below to. 440 rows Axumin fluciclovine F18 Imaging Center Directory If youre a healthcare provider.

For more information on PETCT tests please visit the Radiology Info for Patients website. During this time we understand that access to Axumin PETCT scans in hospitals may be challenging in some US. NORTHERN CALIFORNIA NorCal Imaging Walnut Creek 114 La Casa Via Walnut Creek CA.

200 Medical Plaza Suite B114. If the clinical trials are not suitable for your situation you can get a PSMA PETCT for 2800 at UCLA. 888 738-3211 or 916 737-3211.

To schedule an Axumin PETCT please call us at. For patients interested in access to this type of imaging at present your best resource for finding an Axumin PET scan location near you is to contact the manufacturers. Why should a patient consider going to Shields for his Axumin PET scan.

The total exam is approximately 30-40 minutes. Axumin performed at the following locations.

Understanding And Improving 18f Fluciclovine Pet Ct Reports A Guide For Physicians Treating Patients With Biochemical Recurrence Of Prostate Cancer